HUTCHMED (China) Limited - Asset Resilience Ratio
HUTCHMED (China) Limited (H7T1) has an Asset Resilience Ratio of 73.92% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See HUTCHMED (China) Limited working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how HUTCHMED (China) Limited's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see H7T1 total asset value.
Liquid Assets Composition Over Time
This chart breaks down HUTCHMED (China) Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore H7T1 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €1.30 Billion | 73.92% |
| Total Liquid Assets | €1.30 Billion | 73.92% |
Asset Resilience Insights
- Very High Liquidity: HUTCHMED (China) Limited maintains exceptional liquid asset reserves at 73.92% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
HUTCHMED (China) Limited Industry Peers by Asset Resilience Ratio
Compare HUTCHMED (China) Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for HUTCHMED (China) Limited (2016–2025)
The table below shows the annual Asset Resilience Ratio data for HUTCHMED (China) Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.92% | €1.30 Billion ≈ $1.52 Billion |
€1.75 Billion ≈ $2.05 Billion |
+20.39pp |
| 2024-12-31 | 53.54% | €682.15 Million ≈ $797.51 Million |
€1.27 Billion ≈ $1.49 Billion |
+6.44pp |
| 2023-12-31 | 47.10% | €602.75 Million ≈ $704.67 Million |
€1.28 Billion ≈ $1.50 Billion |
+16.23pp |
| 2022-12-31 | 30.86% | €317.72 Million ≈ $371.45 Million |
€1.03 Billion ≈ $1.20 Billion |
-15.34pp |
| 2021-12-31 | 46.20% | €634.16 Million ≈ $741.40 Million |
€1.37 Billion ≈ $1.60 Billion |
+18.64pp |
| 2020-12-31 | 27.56% | €199.55 Million ≈ $233.29 Million |
€724.12 Million ≈ $846.57 Million |
+6.91pp |
| 2019-12-31 | 20.64% | €96.01 Million ≈ $112.25 Million |
€465.12 Million ≈ $543.78 Million |
-19.75pp |
| 2018-12-31 | 40.39% | €214.91 Million ≈ $251.26 Million |
€532.12 Million ≈ $622.10 Million |
-5.27pp |
| 2017-12-31 | 45.66% | €273.03 Million ≈ $319.20 Million |
€597.93 Million ≈ $699.05 Million |
+38.58pp |
| 2016-12-31 | 7.09% | €24.27 Million ≈ $28.37 Million |
€342.44 Million ≈ $400.34 Million |
-- |
About HUTCHMED (China) Limited
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast c… Read more